These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30010913)

  • 21. Prevalence of Human Papillomavirus Among Females After Vaccine Introduction-National Health and Nutrition Examination Survey, United States, 2003-2014.
    Oliver SE; Unger ER; Lewis R; McDaniel D; Gargano JW; Steinau M; Markowitz LE
    J Infect Dis; 2017 Sep; 216(5):594-603. PubMed ID: 28931217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Facilitators and barriers HPV unvaccinated girls after 5 years of program implementation.
    Firenze A; Marsala MG; Bonanno V; Maranto M; Ferrara C; Giovannelli L; Restivo V
    Hum Vaccin Immunother; 2015; 11(1):240-4. PubMed ID: 25483543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination.
    Mollers M; Scherpenisse M; van der Klis FR; King AJ; van Rossum TG; van Logchem EM; Feltkamp MC; Meijer CJ; Snijders PJ; Boot HJ; de Melker HE
    Cancer Epidemiol; 2012 Dec; 36(6):519-24. PubMed ID: 22906483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of a High Coverage Vaccination Rate on Human Papillomavirus Infection Prevalence in Young Women: A Cross-sectional Study.
    Saldanha C; Vieira-Baptista P; Costa M; Silva AR; Picão M; Sousa C
    J Low Genit Tract Dis; 2020 Oct; 24(4):363-366. PubMed ID: 32796265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Declines in HPV vaccine type prevalence in women screened for cervical cancer in the United States: Evidence of direct and herd effects of vaccination.
    Markowitz LE; Naleway AL; Lewis RM; Crane B; Querec TD; Weinmann S; Steinau M; Unger ER
    Vaccine; 2019 Jun; 37(29):3918-3924. PubMed ID: 31160099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of Vaccine Type Infections in Vaccinated and Non-Vaccinated Young Women: HPV-IMPACT, a Self-Sampling Study.
    Jeannot E; Viviano M; de Pree C; Amadane M; Kabengele E; Vassilakos P; Petignat P
    Int J Environ Res Public Health; 2018 Jul; 15(7):. PubMed ID: 29987255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of 2 and 3 Vaccinations With the Bivalent Human Papillomavirus (HPV) Vaccine on the Prevalence and Load of HPV in Clearing and Persistent Infections in Young Women.
    van Eer K; Middeldorp M; Dzebisasjvili T; Lamkaraf N; de Melker HE; Steenbergen RDM; King AJ
    J Infect Dis; 2023 Oct; 228(8):1012-1022. PubMed ID: 36988110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway.
    Feiring B; Laake I; Bakken IJ; Greve-Isdahl M; Wyller VB; Håberg SE; Magnus P; Trogstad L
    Vaccine; 2017 Jul; 35(33):4203-4212. PubMed ID: 28648542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011-2012 and 2018 : A Cross-sectional Study.
    Baussano I; Tshomo U; Tenet V; Heideman DAM; Wangden T; Franceschi S; Clifford GM
    Ann Intern Med; 2020 Dec; 173(11):888-894. PubMed ID: 32956600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
    Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
    Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
    [No Abstract]   [Full Text] [Related]  

  • 32. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
    Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Impact of Girls-Only Human Papillomavirus 16/18 Vaccination in The Netherlands: Cross-Protective and Second-Order Herd Effects.
    Hoes J; Woestenberg PJ; Bogaards JA; King AJ; de Melker HE; Berkhof J; Hoebe CJPA; van der Sande MAB; van Benthem BHB;
    Clin Infect Dis; 2021 Mar; 72(5):e103-e111. PubMed ID: 33249475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences between vaccinated and unvaccinated women explain increase in non-vaccine-type human papillomavirus in unvaccinated women after vaccine introduction.
    Ding L; Widdice LE; Kahn JA
    Vaccine; 2017 Dec; 35(52):7217-7221. PubMed ID: 29169890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time trends in HPV vaccination according to country background: a nationwide register-based study among girls in Norway.
    Bjerke RD; Laake I; Feiring B; Aamodt G; Trogstad L
    BMC Public Health; 2021 May; 21(1):854. PubMed ID: 33941126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016.
    Mesher D; Panwar K; Thomas SL; Edmundson C; Choi YH; Beddows S; Soldan K
    J Infect Dis; 2018 Aug; 218(6):911-921. PubMed ID: 29917082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses.
    Markowitz LE; Naleway AL; Klein NP; Lewis RM; Crane B; Querec TD; Hsiao A; Aukes L; Timbol J; Weinmann S; Liu G; Steinau M; Unger ER
    J Infect Dis; 2020 Mar; 221(6):910-918. PubMed ID: 31784749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of quadrivalent HPV vaccination in reducing vaccine-type and nonvaccine-type high risk HPV infection.
    Li C; Hall TG; Hall JJ; He WQ
    Epidemiol Infect; 2023 Feb; 151():e37. PubMed ID: 36789960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study.
    Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Garland SM; Cornall AM; Atchison S; Hocking JS; Bradshaw CS; Balgovind P; Murray GL; Chen MY
    Lancet Infect Dis; 2021 Oct; 21(10):1448-1457. PubMed ID: 34043963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Occurrence of human papillomavirus (HPV) type replacement by sexual risk-taking behaviour group: Post-hoc analysis of a community randomized clinical trial up to 9 years after vaccination (IV).
    Gray P; Luostarinen T; Vänskä S; Eriksson T; Lagheden C; Man I; Palmroth J; Pimenoff VN; Söderlund-Strand A; Dillner J; Lehtinen M
    Int J Cancer; 2019 Aug; 145(3):785-796. PubMed ID: 30719706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.